Co-Authors
This is a "connection" page, showing publications co-authored by L JEFFREY MEDEIROS and KEN HE YOUNG.
Connection Strength
5.153
-
Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019 10; 16(10):634-652.
Score: 0.174
-
Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Front Oncol. 2019; 9:107.
Score: 0.167
-
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol. 2018; 8:351.
Score: 0.162
-
Diffuse large B-cell lymphoma. Pathology. 2018 Jan; 50(1):74-87.
Score: 0.153
-
Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev. 2018 01; 32(1):8-28.
Score: 0.150
-
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017 03 23; 129(12):1658-1668.
Score: 0.144
-
Distinguishing Between Hepatosplenic T-cell Lymphoma and ?d T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis. Am J Surg Pathol. 2017 01; 41(1):82-93.
Score: 0.144
-
NF-?B signaling pathway and its potential as a target for therapy in lymphoid neoplasms. Blood Rev. 2017 03; 31(2):77-92.
Score: 0.142
-
Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol. 2016 10; 29(10):1118-42.
Score: 0.140
-
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.
Score: 0.137
-
Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma. 2016 12; 57(12):2804-2812.
Score: 0.137
-
Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13.
Score: 0.134
-
Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev. 2016 05; 30(3):189-200.
Score: 0.133
-
Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91.
Score: 0.131
-
Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases. Am J Surg Pathol. 2015 Aug; 39(8):1132-9.
Score: 0.130
-
Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74.
Score: 0.129
-
Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis. Hematol Oncol. 2017 Mar; 35(1):125-129.
Score: 0.128
-
Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol. 2014 Aug; 18(4):203-9.
Score: 0.119
-
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
Score: 0.116
-
Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. Hum Pathol. 2013 Dec; 44(12):2658-67.
Score: 0.115
-
MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol. 2013 Sep; 20(5):315-26.
Score: 0.114
-
EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013 Jul 18; 122(3):328-40.
Score: 0.112
-
Follicular T-cell lymphoma: a member of an emerging family of follicular helper T-cell derived T-cell lymphomas. Hum Pathol. 2012 Nov; 43(11):1789-98.
Score: 0.107
-
Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol. 2013 Jan; 44(1):110-21.
Score: 0.107
-
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012 Apr 19; 119(16):3668-83.
Score: 0.102
-
Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol. 2012 Apr; 43(4):467-80.
Score: 0.102
-
EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022 Feb; 80(3):575-588.
Score: 0.051
-
Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. Ann Diagn Pathol. 2020 Dec; 49:151636.
Score: 0.047
-
A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol. 2020 03; 33(3):367-379.
Score: 0.043
-
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657.
Score: 0.042
-
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019 06; 32(6):741-754.
Score: 0.041
-
B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018 10 25; 132(17):1805-1817.
Score: 0.040
-
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia. 2018 06; 20(6):574-593.
Score: 0.039
-
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980.
Score: 0.039
-
Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 05 15; 24(10):2304-2311.
Score: 0.039
-
CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol. 2018 02; 31(2):327-336.
Score: 0.038
-
Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol. 2017 Oct; 41(10):1309-1321.
Score: 0.038
-
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget. 2018 Jan 02; 9(1):346-360.
Score: 0.038
-
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716.
Score: 0.037
-
Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844.
Score: 0.037
-
Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445.
Score: 0.037
-
Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (?d) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous ?d T-Cell Lymphomas. Am J Surg Pathol. 2017 Feb; 41(2):204-215.
Score: 0.036
-
Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 06; 7(49):80599-80611.
Score: 0.036
-
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016 12 29; 128(26):3083-3100.
Score: 0.035
-
Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-a inhibitor therapy and literature review. Ann Diagn Pathol. 2017 Feb; 26:16-22.
Score: 0.035
-
Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists. Mol Cytogenet. 2016; 9:62.
Score: 0.035
-
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2016 07 15; 22(14):3593-605.
Score: 0.034
-
Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet. 2016; 9:23.
Score: 0.034
-
p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY). 2016 Feb; 8(2):345-65.
Score: 0.034
-
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):2401-16.
Score: 0.034
-
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016 Jan 10; 34(2):160-8.
Score: 0.033
-
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.
Score: 0.033
-
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2015 Dec; 28(12):1555-73.
Score: 0.033
-
Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of ?d T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With a? T-Cell Large Granular Lymphocytic Leukemia. [corrected]. Am J Clin Pathol. 2015 Oct; 144(4):607-19.
Score: 0.033
-
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. 2015 Oct; 28(10):1297-314.
Score: 0.033
-
Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13.
Score: 0.032
-
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget. 2015 Jun 10; 6(16):13933-45.
Score: 0.032
-
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.
Score: 0.032
-
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Mar 20; 6(8):5615-33.
Score: 0.032
-
CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015 Jun; 28(6):787-98.
Score: 0.032
-
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.
Score: 0.031
-
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Oct 01; 20(19):5113-23.
Score: 0.030
-
Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat. 2014 Aug; 147(1):1-14.
Score: 0.030
-
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29.
Score: 0.030
-
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49.
Score: 0.030
-
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014 Jul; 27(7):958-71.
Score: 0.029
-
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40.
Score: 0.029
-
CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014 Mar; 55(3):624-7.
Score: 0.028
-
Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. Am J Surg Pathol. 2013 Aug; 37(8):1290-7.
Score: 0.028
-
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 30; 121(22):4529-40.
Score: 0.028
-
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 16; 121(20):4021-31; quiz 4250.
Score: 0.028
-
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 04; 121(14):2715-24.
Score: 0.027
-
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Nov 08; 120(19):3986-96.
Score: 0.027
-
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013 Feb; 98(2):255-63.
Score: 0.027
-
High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology. 2012 Nov; 61(5):945-54.
Score: 0.026
-
Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol. 2012 Jul; 36(7):1000-8.
Score: 0.026
-
Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol. 2012 Sep; 43(9):1347-62.
Score: 0.026